Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lidocaine vs Duloxetine for CIPN in Breast Cancer
NCT04732455Completed
- Start
- Jan 2021
- Primary completion
- Jun 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, single-blind trial of Lidocaine Hydrochloride Injection, without epinephrine and duloxetine in chemotherapy-induced peripheral neuropathy (CIPN). Primary endpoint: Neuropathy Pain Scale at 12 weeks. Started Jan 2021; status: completed.
02
Drugs
Lidocaine Hydrochloride Injection, without epinephrineduloxetine
03
Conditions
chemotherapy-induced peripheral neuropathy (CIPN)
Beyond the preview
Go deeper on NCT04732455.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04732455.